Biodegradable injectable implant systems for long term drug delivery using poly (lactic-co-glycolic) acid copolymers

G. Chandrashekar, N. Udupa

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Poly (lactide-co-glycolide) (PLG), is one of the most widely employed biodegradable synthetic polymers for sustained-release preparations. In the present work, PLG (50:50) copolymer has been used to deliver diclofenac sodium in the form of microspheres and in situ gel-forming systems, both of which can be injected subcutaneously. The pharmacodynamic and pharmacokinetic studies in the adjuvant-induced arthritic rats showed that the microspheres offered steady therapeutic levels of the drug in the plasma for about 16 days following a single subcutaneous injection. However, the in situ gel-forming system provided a significantly higher maximum plasma concentration and increased inhibition of inflammation, maintained for about 10 days. Injectable microspheres and in situ gel-forming implant systems of PLG (50:50) copolymer may therefore be considered as prospective implantable controlled-release dosage forms to deliver drugs in long-term therapy of chronic ailments.

Original languageEnglish
Pages (from-to)669-674
Number of pages6
JournalJournal of Pharmacy and Pharmacology
Volume48
Issue number7
Publication statusPublished - 07-1996

Fingerprint

Absorbable Implants
Microspheres
Gels
Injections
Pharmaceutical Preparations
Delayed-Action Preparations
Polyglactin 910
Experimental Arthritis
Diclofenac
Dosage Forms
Subcutaneous Injections
Polymers
Pharmacokinetics
Inflammation
Therapeutics
polylactic acid-polyglycolic acid copolymer

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science

Cite this

@article{05d30e680af44a37822f31bafc9e1883,
title = "Biodegradable injectable implant systems for long term drug delivery using poly (lactic-co-glycolic) acid copolymers",
abstract = "Poly (lactide-co-glycolide) (PLG), is one of the most widely employed biodegradable synthetic polymers for sustained-release preparations. In the present work, PLG (50:50) copolymer has been used to deliver diclofenac sodium in the form of microspheres and in situ gel-forming systems, both of which can be injected subcutaneously. The pharmacodynamic and pharmacokinetic studies in the adjuvant-induced arthritic rats showed that the microspheres offered steady therapeutic levels of the drug in the plasma for about 16 days following a single subcutaneous injection. However, the in situ gel-forming system provided a significantly higher maximum plasma concentration and increased inhibition of inflammation, maintained for about 10 days. Injectable microspheres and in situ gel-forming implant systems of PLG (50:50) copolymer may therefore be considered as prospective implantable controlled-release dosage forms to deliver drugs in long-term therapy of chronic ailments.",
author = "G. Chandrashekar and N. Udupa",
note = "cited By 63",
year = "1996",
month = "7",
language = "English",
volume = "48",
pages = "669--674",
journal = "Journal of Pharmacy and Pharmacology",
issn = "0022-3573",
publisher = "Pharmaceutical Press",
number = "7",

}

Biodegradable injectable implant systems for long term drug delivery using poly (lactic-co-glycolic) acid copolymers. / Chandrashekar, G.; Udupa, N.

In: Journal of Pharmacy and Pharmacology, Vol. 48, No. 7, 07.1996, p. 669-674.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Biodegradable injectable implant systems for long term drug delivery using poly (lactic-co-glycolic) acid copolymers

AU - Chandrashekar, G.

AU - Udupa, N.

N1 - cited By 63

PY - 1996/7

Y1 - 1996/7

N2 - Poly (lactide-co-glycolide) (PLG), is one of the most widely employed biodegradable synthetic polymers for sustained-release preparations. In the present work, PLG (50:50) copolymer has been used to deliver diclofenac sodium in the form of microspheres and in situ gel-forming systems, both of which can be injected subcutaneously. The pharmacodynamic and pharmacokinetic studies in the adjuvant-induced arthritic rats showed that the microspheres offered steady therapeutic levels of the drug in the plasma for about 16 days following a single subcutaneous injection. However, the in situ gel-forming system provided a significantly higher maximum plasma concentration and increased inhibition of inflammation, maintained for about 10 days. Injectable microspheres and in situ gel-forming implant systems of PLG (50:50) copolymer may therefore be considered as prospective implantable controlled-release dosage forms to deliver drugs in long-term therapy of chronic ailments.

AB - Poly (lactide-co-glycolide) (PLG), is one of the most widely employed biodegradable synthetic polymers for sustained-release preparations. In the present work, PLG (50:50) copolymer has been used to deliver diclofenac sodium in the form of microspheres and in situ gel-forming systems, both of which can be injected subcutaneously. The pharmacodynamic and pharmacokinetic studies in the adjuvant-induced arthritic rats showed that the microspheres offered steady therapeutic levels of the drug in the plasma for about 16 days following a single subcutaneous injection. However, the in situ gel-forming system provided a significantly higher maximum plasma concentration and increased inhibition of inflammation, maintained for about 10 days. Injectable microspheres and in situ gel-forming implant systems of PLG (50:50) copolymer may therefore be considered as prospective implantable controlled-release dosage forms to deliver drugs in long-term therapy of chronic ailments.

UR - http://www.scopus.com/inward/record.url?scp=0029789140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029789140&partnerID=8YFLogxK

M3 - Article

VL - 48

SP - 669

EP - 674

JO - Journal of Pharmacy and Pharmacology

JF - Journal of Pharmacy and Pharmacology

SN - 0022-3573

IS - 7

ER -